Point View Wealth Management Inc. Has $1.74 Million Stake in Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

[ad_1]

Point View Wealth Management Inc. lifted its stake in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 4.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 71,603 shares of the company’s stock after purchasing an additional 2,996 shares during the period. Point View Wealth Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $1,741,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in TEVA. Global X Management Co. LLC bought a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at $123,000. Sheaff Brock Investment Advisors LLC bought a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at $177,000. ETRADE Capital Management LLC bought a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at $188,000. Financial Advisory Service Inc. bought a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at $188,000. Finally, Wealthstreet Investment Advisors LLC bought a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at $200,000. Institutional investors own 64.52% of the company’s stock.

A number of equities research analysts recently weighed in on the company. Mizuho restated a “buy” rating and issued a $28.00 price target on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 16th. Wells Fargo & Co set a $23.00 price target on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Thursday, August 2nd. Royal Bank of Canada reaffirmed a “hold” rating and issued a $19.00 price objective on shares of Teva Pharmaceutical Industries in a report on Tuesday, July 31st. Zacks Investment Research raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $27.00 price objective on the stock in a report on Monday, July 9th. Finally, Credit Suisse Group lowered Teva Pharmaceutical Industries from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $25.00 to $23.00 in a report on Friday. Eight investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and seven have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $20.70.

Shares of TEVA traded up $0.82 during trading hours on Tuesday, hitting $21.88. 13,708,300 shares of the company were exchanged, compared to its average volume of 12,857,474. The firm has a market cap of $21.86 billion, a P/E ratio of 5.57, a price-to-earnings-growth ratio of 2.68 and a beta of 0.70. Teva Pharmaceutical Industries Ltd has a fifty-two week low of $10.85 and a fifty-two week high of $25.96. The company has a debt-to-equity ratio of 1.86, a quick ratio of 0.69 and a current ratio of 1.03.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Thursday, August 2nd. The company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.14. The company had revenue of $4.70 billion for the quarter, compared to analyst estimates of $4.75 billion. Teva Pharmaceutical Industries had a positive return on equity of 19.92% and a negative net margin of 47.98%. Teva Pharmaceutical Industries’s quarterly revenue was down 17.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.02 EPS. research analysts predict that Teva Pharmaceutical Industries Ltd will post 2.67 earnings per share for the current fiscal year.

In other Teva Pharmaceutical Industries news, EVP Sven Dethlefs acquired 2,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Friday, August 3rd. The shares were acquired at an average cost of $21.92 per share, with a total value of $43,840.00. Following the completion of the purchase, the executive vice president now directly owns 6,445 shares of the company’s stock, valued at approximately $141,274.40. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Iris Beck Codner sold 4,165 shares of the firm’s stock in a transaction dated Thursday, August 9th. The shares were sold at an average price of $22.70, for a total value of $94,545.50. Following the completion of the sale, the executive vice president now directly owns 8,290 shares in the company, valued at $188,183. The disclosure for this sale can be found here. Corporate insiders own 0.43% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: How is a Moving Average Calculated?

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *